[2006] HCATrans 271
IN THE HIGH COURT OF AUSTRALIA
Office of the Registry
Melbourne No M150 of 2005
B e t w e e n -
PFIZER OVERSEAS PHARMACEUTICALS
First Applicant
PFIZER AUSTRALIA PTY LTD
Second Applicant
C P PHARMACEUTICALS INTERNATIONAL CV
Third Applicant
PFIZER MANUFACTURING LLC
Fourth Applicant
PFIZER PRODUCTION LLC
Fifth Applicant
and
ELI LILLY & COMPANY
First Respondent
ELI LILLY AUSTRALIA PTY LTD
Second Respondent
ELI LILLY & COMPANY LTD
Third Respondent
Application for special leave to appeal
GLEESON CJ
HAYNE J
TRANSCRIPT OF PROCEEDINGS
AT MELBOURNE ON FRIDAY, 2 JUNE 2006, AT 11.31 AM
Copyright in the High Court of Australia
__________________
MR D. SHAVIN, QC: May it please the Court, I appear for the applicant with my learned friend, MS H.M.J. ROFE. (instructed by Corrs Chambers Westgarth)
MR D.K. CATTERNS, QC: May it please the Court, I appear with my learned friend, MS K.J. HOWARD, for the respondents. (instructed by Blake Dawson Waldron)
GLEESON CJ: Yes, Mr Shavin.
MR SHAVIN: If the Court pleases. The case raises for consideration the issue of the meaning of the words “matter described in the specification” in section 40(3) of the Patents Act 1990 in a way that has not previously been considered by this Court. The question which sharply divided the Federal Court below was what constituted a fair basis for a claim where the specification contained what Justice Crennan described at paragraph 422 of her judgment as a broad disclosure and a narrow disclosure and there are claims as to both.
GLEESON CJ: I had an impression, correct me if am wrong, that the question that divided the majority and the minority in the Federal Court was a question of construction of the specification.
MR SHAVIN: In our respectful submission, no, your Honour, for this reason. The patent discloses a method of treatment for erectile dysfunction. The patent commences its discussion by saying it relates to a very wide class of compounds and there is disclosed a new use for a class of compounds, compounds that were previously disclosed in the Bell patent referred to on page 7 of the specification. There is also disclosed within the specification the pharmacological action which mediates the treatment and that pharmacological action explains not only why that class of compounds can be used as a method of treatment, but also discloses how you engage in the treatment and that is said so expressly at the foot of page 9 to the top of page 10 of the specification.
The majority, in approaching the specification, looked only to the class of compounds. They looked only to words which they sought to attribute a description of the invention. In a sense they looked to words akin to a consistory clause and said that is all to which we will look. They did not look or consider in the context of fair basis the broader disclosure. They averted the process, whereas this Court affirmed the statement of Justice Gummow…
Keep reading for free
Create a free CaseChat account to read Pfizer Overseas Pharmaceuticals & Ors v Eli Lilly & Co & Ors and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2006] HCATrans 271
- Decision Date
CaseChat Overview and Summary
The primary legal issue before the High Court was whether the respondents' patent claims, specifically claims 1 and 2, were valid and infringed by the appellants. This involved a determination of whether the patent sufficiently disclosed the invention, particularly in relation to the compound's therapeutic use, and whether the claims were novel and involved an inventive step. The appellants contended that the patent lacked sufficient disclosure and that the claimed invention was obvious in light of prior art.
The High Court, in a joint judgment delivered by Gleeson CJ and Hayne J, found that the patent claims were valid. Their Honours reasoned that the patent specification adequately disclosed the invention, including the therapeutic use of duloxetine, by providing sufficient information to enable a skilled person to identify and use the compound for its intended purpose. The Court applied the principles of patent law concerning sufficiency of disclosure, novelty, and inventive step, finding that the respondents had met the requirements of the Patents Act 1990 (Cth). The appeal was accordingly dismissed.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi